Seong Hoon Yoon
Overview
Explore the profile of Seong Hoon Yoon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho E, Yi J, Chun J, Jang H, Yoon S, Lee S, et al.
Integr Cancer Ther
. 2025 Feb;
24:15347354251319339.
PMID: 39985390
Background: Non-small cell lung cancer (NSCLC) exhibits low survival rates. Although immune checkpoint inhibitors (ICIs) have become first-line treatment for NSCLC, their limited response to ICI monotherapy has led to...
2.
Lee Y, Kwon R, Lee H, Chung J, Kim Y, Jeong H, et al.
Pharmaceutics
. 2025 Jan;
17(1).
PMID: 39861671
Lung cancer remains a major global health problem because of its high cancer-related mortality rate despite advances in therapeutic approaches. Non-small cell lung cancer (NSCLC), a major subtype of lung...
3.
Yeo C, Park D, Yoon S, Kim E, Lee J, Lee S, et al.
Clin Respir J
. 2025 Jan;
19(1):e70043.
PMID: 39757012
Introduction: The provision of treatment for epidermal growth factor receptor (EGFR)-mutated nonsmall cell lung cancer (NSCLC) patients has increased in Korea. However, multicenter studies on the clinicopathologic dataset and treatment...
4.
Seol H, Chae G, Kim J, Kim Y, Yoon S, Lee T
Respirol Case Rep
. 2024 Sep;
12(9):e70017.
PMID: 39253320
As the demand for advanced bronchoscopic procedures increases, prolonged sedation with adequate oxygenation has become essential. Traditionally, these procedures require an anesthesiologist to provide (positive-pressure or jet) ventilator support. However,...
5.
Kwag E, Kim S, Shin S, Oak C, Park S, Choi J, et al.
Integr Cancer Ther
. 2024 Aug;
23:15347354241268231.
PMID: 39103991
Background: Lung cancer, especially non-small cell lung cancer (NSCLC), poses a significant health challenge globally due to its high mortality. Afatinib, a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),...
6.
Kang D, Choi C, Park C, Oh I, Kim Y, Yoon S, et al.
Tuberc Respir Dis (Seoul)
. 2024 May;
87(4):483-493.
PMID: 38749491
Background: The use of immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer is increasing. Despite ongoing studies to predict the efficacy of ICIs, its use in clinical practice...
7.
Yoon S, Vandal A, Rivera-Rodriguez C
Stat Methods Med Res
. 2024 Mar;
33(4):728-742.
PMID: 38444359
Joint modelling of longitudinal and time-to-event data is a method that recognizes the dependency between the two data types, and combines the two outcomes into a single model, which leads...
8.
Kim H, Lee J, Oh I, Kim E, Yoon S, Lee S, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339278
Real-world data on the use and outcomes of crizotinib in ROS1-rearranged non-small-cell lung cancer (NSCLC) are limited. This study aims to analyze the real-world efficacy of crizotinib in South Korea...
9.
Jeon D, Park C, Kim S, Park C, Chang Y, Jung C, et al.
Thorac Cancer
. 2024 Jan;
15(6):448-457.
PMID: 38171544
Background: About 3%-5% of non-small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK-positive NSCLC. This study...
10.
Choi J, Choi C, Chang Y, Lee K, Kim S, Yang S, et al.
Transl Lung Cancer Res
. 2023 Dec;
12(11):2275-2282.
PMID: 38090523
Background: Data from clinical trials and real-world studies show that afatinib is effective in treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor ()...